Portal de Periódicos da CAPES

Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta‐analysis

2012; Wiley; Volume: 21; Issue: 11 Linguagem: Inglês

10.1002/pds.3309

1099-1557

Ana Miguel, Luís Filipe Azevedo, M. Beatriz D. G Araujo, Altamiro Costa‐Pereira,

Pharmacovigilance and Adverse Drug Reactions

ABSTRACT Purposes To perform a comprehensive systematic review of prospective studies about frequency of adverse drug reactions (ADRs) occurring during hospitalization (ADR In ), including a thorough study quality assessment, meta‐analysis and heterogeneity evaluation. Methods Systematic review of several databases: Pubmed, EMBASE, CINAHL, Cochrane, ISI, International Pharmaceutical Abstracts, Scirus, NHS economic, and others, as well as manual search. Inclusion criteria were: prospective studies (assessing all patients before discharge, by a specialized team, at least once a week); with data about ADRs occurring during hospitalization, using WHO's or similar definition of ADR. Two independent reviewers assessed eligibility criteria, extracted data, and evaluated risk of bias. Results From 4139 studies initially found, 22 were included. Meta‐analysis indicate that ADRs may occur in 16.88% (CI95%: 13.56,20.21%) of patients during hospitalization; however, this estimate has to be viewed with caution because there was significant heterogeneity ( I 2 = 99%). The most significant moderators of heterogeneity were risk of bias, population, ward, and methodology for ADR identification. Low risk of bias studies adjusted for population (pediatric versus adult) had I 2 = 0%. Conclusions These data are useful as a broad characterization of in‐hospital ADRs and their frequency. However, due to heterogeneity, our estimates are crude indicators. The wide variation in methodologies was one of the most important moderators of heterogeneity (even among studies using intensive monitoring). We suggest criteria to standardize methodologies and reduce the risk of bias. Copyright © 2012 John Wiley & Sons, Ltd.